Welcome to our dedicated page for Oncocyte Corporation SEC filings (Ticker: OCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a science-driven company like Oncocyte means wading through pages of clinical-trial updates, FDA-risk language and detailed R&D footnotes. If you have ever searched for Oncocyte insider trading Form 4 transactions or tried to parse dilution clauses buried in a 10-K, you know the challenge. Stock Titan solves this problem by turning every new disclosure into clear, actionable intelligence in seconds.
Our platform ingests each Oncocyte quarterly earnings report 10-Q filing, 8-K data drop and proxy statement the moment it hits EDGAR, then deploys AI to surface what matters: trial-milestone dates, cash-burn trends and leadership moves. With plain-language summaries, you’ll see Oncocyte annual report 10-K simplified, receive alerts on Oncocyte Form 4 insider transactions real-time, and get line-by-line commentary that makes understanding Oncocyte SEC documents with AI effortless. Whether you’re monitoring Oncocyte executive stock transactions Form 4, reviewing an Oncocyte earnings report filing analysis, or checking an Oncocyte 8-K material events explained note, the insights appear automatically—no scrolling through PDFs.
Professionals use these AI-powered summaries to compare segment revenue from liquid-biopsy assays, gauge the probability of FDA clearance, or verify details inside an Oncocyte proxy statement executive compensation section before voting. Real-time updates, comprehensive coverage of every form type, and concise expert context let you act sooner on critical developments—all while leaving the dense scientific jargon to us.
Color Star Technology Co., Ltd. (NASDAQ: ADD) reported the results of its 29 June 2025 Annual General Meeting in a Form 6-K filing. Holders of 17,083,723 ordinary shares, representing 57.9 % of outstanding shares, formed a quorum and approved every agenda item.
Key resolutions:
- Reverse Share Split & Share Consolidation: Board may implement a reverse split at a ratio between 1-for-5 and 1-for-100. This reduces the share count and raises the par value while keeping authorised capital at US$32 million. Vote: 99.0 % in favour (16.92 m For / 0.16 m Against).
- Corporate Rebrand: Company name will change to Zeta Network Group. Vote: 99.3 % in favour (16.97 m For).
- Articles Amendment: Adoption of a Seventh Amended & Restated Memorandum and Articles to reflect the share consolidation and name change (99.3 % support).
- 2025 Equity Incentive Plan: Authorises new share-based awards; passed with 99.1 % support.
- Board Elections: Five directors (Wei Zhang, Hung-Jen Kuo, Honglei Jiang, Yan Zhang, Samantha Huang) re-elected with ~99.2 % approval each.
- Auditor Ratification: Assentsure PAC retained for FY 2025 (99.5 % approval).
- Routine filings and adjournment authorities also approved.
Implications for investors: The reverse split authority provides flexibility to lift a depressed share price or meet exchange listing requirements, but may compress existing shareholdings depending on the final ratio chosen. The equity plan could introduce dilution over time, while the rebrand signals a strategic repositioning. No financial performance metrics were disclosed in this filing.
Color Star Technology Co., Ltd. (NASDAQ: ADD) reported the results of its 29 June 2025 Annual General Meeting in a Form 6-K filing. Holders of 17,083,723 ordinary shares, representing 57.9 % of outstanding shares, formed a quorum and approved every agenda item.
Key resolutions:
- Reverse Share Split & Share Consolidation: Board may implement a reverse split at a ratio between 1-for-5 and 1-for-100. This reduces the share count and raises the par value while keeping authorised capital at US$32 million. Vote: 99.0 % in favour (16.92 m For / 0.16 m Against).
- Corporate Rebrand: Company name will change to Zeta Network Group. Vote: 99.3 % in favour (16.97 m For).
- Articles Amendment: Adoption of a Seventh Amended & Restated Memorandum and Articles to reflect the share consolidation and name change (99.3 % support).
- 2025 Equity Incentive Plan: Authorises new share-based awards; passed with 99.1 % support.
- Board Elections: Five directors (Wei Zhang, Hung-Jen Kuo, Honglei Jiang, Yan Zhang, Samantha Huang) re-elected with ~99.2 % approval each.
- Auditor Ratification: Assentsure PAC retained for FY 2025 (99.5 % approval).
- Routine filings and adjournment authorities also approved.
Implications for investors: The reverse split authority provides flexibility to lift a depressed share price or meet exchange listing requirements, but may compress existing shareholdings depending on the final ratio chosen. The equity plan could introduce dilution over time, while the rebrand signals a strategic repositioning. No financial performance metrics were disclosed in this filing.
Synchrony Financial (SYF) filed a Form 4 on 2 Jul 2025 disclosing a routine equity award to director Fernando Aguirre. On 30 Jun 2025 Aguirre received 825 restricted stock units (RSUs) classified under transaction code “A” (grant). The filing lists an indicative price of $66.74, though RSUs do not require cash payment. The award will vest in full on 30 Jun 2026; each RSU converts into one share of SYF common stock.
Following the grant, Aguirre’s direct ownership rises to 27,097 common shares. He also reports 15,300 shares held indirectly through family trusts, bringing his total reported economic exposure to 42,397 shares. No open-market purchases, sales, or derivative transactions were reported, and there were no amendments to previous filings.
The size of the award represents a modest increase—roughly 3% of Aguirre’s previously reported direct holdings and an immaterial fraction of SYF’s ~420 million shares outstanding. As such, the transaction is viewed as a standard board compensation event that marginally aligns director incentives with shareholder interests but carries no material impact on the company’s capital structure or valuation.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What is the core focus of Oncocyte Corporation?
How do Oncocyte’s diagnostic tests work?
Which medical conditions does Oncocyte target?
What makes Oncocyte’s approach unique in the diagnostics industry?
Who are some of Oncocyte’s strategic partners?
How do liquid biopsy diagnostics benefit patient care?
What technologies underpin Oncocyte’s diagnostic assays?
How does Oncocyte differentiate itself from competitors?
